
  
    
      
        Background_NNP
        Opioid_NNP receptors_NNS (_( ORs_NNP )_) ,_, like_IN many_JJ other_JJ G_NNP
        protein-coupled_JJ receptors_NNS (_( GPCRs_NNP )_) ,_, are_VBP capable_JJ of_IN
        signalling_VBG via_IN the_DT family_NN of_IN mitogen_NN activated_VBN protein_NN
        kinases_NNS (_( MAPKs_NNP )_) ._. It_PRP has_VBZ been_VBN postulated_JJ that_DT activation_NN of_IN
        these_DT kinases_NNS allows_VBZ GPCR_NNP agonists_NNS to_TO modulate_VBP such_JJ diverse_JJ
        molecular_JJ events_NNS as_IN cell_NN proliferation_NN ,_, differentiation_NN ,_,
        and_CC survival_NN [_NN 1_CD ]_NN ._. To_TO date_NN ,_, all_DT three_CD cloned_VBN opioid_NN
        receptor_NN types_NNS (_( μ_NN ,_, δ_NN ,_, κ_NN )_) and_CC the_DT closely_RB related_VBN nociceptin_NN
        receptor_NN have_VBP demonstrated_VBN the_DT ability_NN to_TO signal_VB through_IN
        their_PRP$ heterotrimeric_JJ G_NNP proteins_NNS (_( G_NNP 
        i_NNP or_CC G_NNP 
        o_NN )_) to_TO at_IN least_JJS one_CD type_NN of_IN MAPK_NNP [_NN 2_CD 3_CD 4_CD
        ]_NN ._. Among_IN the_DT members_NNS of_IN this_DT family_NN that_WDT are_VBP activated_VBN by_IN
        opioids_NNS ,_, are_VBP the_DT two_CD extracellular_NN signal-regulated_JJ protein_NN
        kinases_NNS (_( p_NN 44_CD MAPK_NNP (_( ERK_NNP 1_LS )_) and_CC p_NN 42_CD MAPK_NNP (_( ERK_NNP 2_LS )_) )_) [_NN 5_CD ]_NN and_CC the_DT
        p_NN 38_CD protein_NN kinase_NN [_NN 3_CD ]_NN ._. However_RB ,_, the_DT precise_JJ mechanism_NN
        by_IN which_WDT OR_NNP stimulation_NN produces_VBZ an_DT increase_NN in_IN MAPK_NNP
        activity_NN is_VBZ still_RB unknown_JJ and_CC under_IN investigation_NN ._.
        While_IN receptor_NN ,_, cell_NN ,_, and_CC tissue-specific_JJ differences_NNS
        almost_RB certainly_RB exist_VB and_CC appear_VB to_TO make_VB any_DT single_JJ
        mechanism_NN of_IN ERK_NNP activation_NN unlikely_JJ ,_, certain_JJ generalities_NNS
        have_VBP begun_VBN to_TO emerge_VB ._. For_IN example_NN ,_, ERK_NNP activation_NN by_IN GPCRs_NNP
        is_VBZ predominantly_RB a_DT Ras-dependent_NNP event_NN ,_, one_CD that_WDT utilizes_NNS
        many_JJ of_IN the_DT upstream_JJ protein_NN intermediates_NNS (_( i_NNP ._. e_SYM ._. Shc_NNP ,_, Gab_NNP 1_CD ,_,
        Grb_NNP 2_CD ,_, mSOS_NN ,_, and_CC MAPK_NNP kinase_NN (_( MEK-_NNP 1_LS )_) )_) known_VBN to_TO be_VB used_VBN by_IN
        single-transmembrane_JJ receptor_NN tyrosine_NN kinases_NNS (_( RTKs_NNP )_) like_IN
        the_DT epidermal_NN growth_NN factor_NN receptor_NN (_( EGFR_NNP )_) (_( for_IN a_DT review_NN
        see_VB [_NN 6_CD ]_NN )_) ._. When_WRB ERKs_NNP are_VBP activated_VBN after_IN EGFR_NNP
        stimulation_NN ,_, an_DT essential_JJ event_NN is_VBZ the_DT sequential_NN tyrosine_NN
        phosphorylation_NN of_IN these_DT intermediate_JJ proteins_NNS and_CC their_PRP$
        binding_JJ to_TO the_DT tyrosine_NN phosphorylated_JJ EGFR_NNP before_IN the_DT
        GTP-loading_NNP of_IN Ras_NNP ._. For_IN the_DT GPCR_NNP model_NN ,_, the_DT tyrosine_NN
        kinase_NN (_( s_VBZ )_) involved_VBN and_CC the_DT site_NN of_IN this_DT multi-protein_JJ
        complex_JJ formation_NN is_VBZ less_RBR clear_JJ ._. For_IN a_DT number_NN of_IN GPCRs_NNP ,_,
        including_VBG the_DT lysophosphatidic_JJ acid_NN (_( LPAR_NNP )_) [_NN 7_CD ]_NN ,_,
        β-adrenergic_JJ 
        2_CD (_( β_NN 
        2_CD -_: AR_NNP )_) [_NN 8_CD ]_NN and_CC μ-_NN and_CC δ-_NN OR_NNP receptors_NNS [_NN
        9_CD ]_NN ,_, the_DT activation_NN of_IN a_DT non-receptor_JJ tyrosine_NN kinase_NN of_IN
        the_DT Src_NNP or_CC focal_JJ adhesion_NN kinase_NN (_( FAK_NNP )_) [_NN 10_CD ]_NN families_NNS are_VBP
        involved_VBN ._. However_RB ,_, the_DT question_NN of_IN what_WP plasma_NN
        membrane-spanning_JJ protein_NN serves_VBZ as_IN the_DT scaffold_NN for_IN Shc_NNP
        binding_JJ and_CC beyond_IN remains_VBZ to_TO be_VB answered_VBN ._.
        Two_CD possibilities_NNS have_VBP emerged_VBN as_IN potential_JJ sites_NNS of_IN
        tyrosine_NN phosphorylation_NN and_CC subsequent_JJ scaffold_NN building_NN
        in_IN response_NN to_TO GPCR_NNP stimulation_NN ,_, which_WDT results_VBZ in_IN ERK_NNP
        activation_NN :_: the_DT GPCR_NNP ,_, itself_PRP ,_, or_CC a_DT co-expressed_JJ RTK_NNP (_( i_NNP ._. e_SYM ._.
        the_DT EGFR_NNP )_) that_WDT would_MD act_VB as_IN a_DT surrogate_NN ._. We_PRP and_CC others_NNS and_CC
        we_PRP have_VBP reported_VBN that_DT μ-_NN and_CC δ-opioid_JJ receptors_NNS become_VBP
        tyrosine_NN phosphorylated_JJ after_IN agonist-stimulation_JJ [_NN 11_CD 12_CD ]_NN
        ._. Tyrosine_NNP phosphorylation_NN of_IN a_DT membrane-bound_JJ protein_NN is_VBZ
        an_DT essential_JJ step_NN in_IN ERK_NNP activation_NN ,_, because_IN it_PRP creates_VBZ
        SH_NNP 2_CD -_: binding_JJ domains_NNS that_WDT allow_VBP Shc_NNP and_CC other_JJ proteins_NNS to_TO
        associate_JJ into_IN a_DT multi-protein_JJ signalling_VBG complex_JJ ._. The_DT
        mutation_NN of_IN one_CD of_IN the_DT tyrosines_NNS (_( Y_NNP 318_CD F_NN )_) in_IN the_DT δ-_NN OR_NNP or_CC the_DT
        presence_NN of_IN the_DT Src_NNP inhibitor_NN ,_, PP_NNP 1_CD ,_, significantly_RB reduces_VBZ
        tyrosine_NN phosphorylation_NN of_IN this_DT receptor_NN and_CC its_PRP$ ability_NN
        to_TO activate_VBP ERKs_NNP [_NN 11_CD 13_CD ]_NN ._. However_RB ,_, a_DT small_JJ degree_NN of_IN
        δ-_NN OR_NNP agonist-mediated_JJ ERK_NNP activation_NN remained_VBD in_IN cells_NNS
        expressing_VBG the_DT Y_NNP 318_CD F_NN mutant_JJ receptor_NN ,_, suggesting_VBG that_IN a_DT
        second_JJ mechanism_NN or_CC an_DT additional_JJ tyrosine_NN could_MD be_VB
        involved_VBN ._. These_DT data_NNS suggest_VBP that_IN the_DT tyrosine_NN
        phosphorylation_NN of_IN GPCRs_NNP may_MD allow_VB them_PRP to_TO signal_VB ERKs_NNP in_IN
        the_DT absence_NN of_IN RTK_NNP or_CC FAK_NNP phosphorylation_NN by_IN acting_VBG as_IN
        their_PRP$ own_JJ scaffolds_NNS ._.
        However_RB ,_, the_DT majority_NN of_IN the_DT published_VBN studies_NNS have_VBP
        focused_VBN on_IN the_DT hypothesis_NNS that_IN GPCRs_NNP must_MD work_VB in_IN
        cooperation_NN with_IN RTKs_NNP (_( i_NNP ._. e_SYM ._. the_DT EGFR_NNP )_) to_TO produce_VB ERK_NNP
        activation_NN ._. Studies_NNS by_IN Daub_NNP et_CC al_NN ._. ,_, [_NN 7_CD ]_NN and_CC Luttrell_NNP et_CC
        al_NN ._. ,_, [_NN 14_CD ]_NN have_VBP demonstrated_VBN that_DT stimulation_NN of_IN LPAR_NNP (_( G_NNP 
        i_NNP /_NN q_NN -_: coupled_VBN )_) and_CC β_NN 
        2_CD -_: ARs_NNP (_( G_NNP 
        s_VBZ -_: coupled_VBN )_) ,_, respectively_RB ,_, results_NNS in_IN
        the_DT "_'' transactivation_NN /_NN transphosphorylation_NN "_'' of_IN co-expressed_JJ
        EGFRs_NNP ._. For_IN example_NN ,_, both_DT EPA_NNP and_CC isoproterenol_NN increase_NN the_DT
        tyrosine_NN phosphorylation_NN of_IN the_DT EGFR_NNP ,_, which_WDT appears_VBZ to_TO be_VB
        required_VBN for_IN ERK_NNP activation_NN since_IN the_DT presence_NN of_IN
        kinase-deficient_JJ EGFR_NNP mutants_NNS or_CC the_DT kinase_NN inhibitor_NN ,_,
        AG_NNP 1478_CD ,_, prevents_VBZ both_DT responses_NNS ._. It_PRP is_VBZ hypothesized_VBN that_IN
        trans-tyrosine_JJ phosphorylation_NN of_IN the_DT EGFR_NNP creates_VBZ protein_NN
        phosphotyrosine_NN binding_JJ sites_NNS that_WDT act_NN as_IN a_DT surrogate_JJ
        scaffold_NN for_IN ERK_NNP activation_NN [_NN 7_CD ]_NN ._. Since_IN ORs_NNP share_NN many_JJ
        similarities_NNS with_IN LPAR_NNP and_CC β_NN 
        2_CD -_: ARs_NNP in_IN the_DT way_NN they_PRP activate_VBP the_DT ERK_NNP
        pathway_NN [_NN 9_CD 15_CD ]_NN ,_, we_PRP chose_VBD to_TO examine_VB whether_IN RTK_NNP
        transactivation_NN occurs_VBZ and_CC is_VBZ a_DT necessary_JJ aspect_NN of_IN
        δ-opioid-mediated_JJ ERK_NNP activation_NN ._.
      
      
        Results_NNS
        
          DSLET_NNP and_CC EGF_NNP induce_VB ERK_NNP phosphorylation_NN in_IN
          δ-_NN OR-expressing_NNP HEK-_NNP 293_CD cells_NNS
          We_PRP have_VBP shown_VBN that_IN δ-opioids_JJ increase_NN the_DT
          phosphorylation_NN of_IN ERKl_NNP /_NN 2_CD in_IN HEK-_NNP 293_CD cells_NNS when_WRB the_DT mouse_NN
          wild_JJ type_NN (_( WT_NNP )_) δ-_NN OR_NNP is_VBZ stably_RB expressed_VBN [_NN 11_CD 13_CD ]_NN ._. The_DT
          concentrations_NNS required_VBN to_TO observe_VB DSLET-mediated_NNP ERK_NNP
          phosphorylation_NN (_( EC_NNP 
          50_CD =_SYM 10_CD nM_NN ;_: Figure_NN 1_CD a_DT )_) are_NN consistent_JJ
          with_IN those_DT reported_VBN for_IN other_JJ δ-_NN OR-mediated_NNP events_NNS ,_,
          including_VBG G_NNP protein_NN activation_NN and_CC adenylyl_NN cyclase_NN
          inhibition_NN [_NN 16_CD 17_CD ]_NN ._. Moreover_RB ,_, no_DT change_NN in_IN total_JJ ERK_NNP
          expression_NN was_VBD observed_VBN ,_, concomitantly_RB ,_, with_IN ERK_NNP
          phosphorylation_NN in_IN any_DT of_IN our_PRP$ experiments_NNS (_( data_NNS not_RB
          shown_VBN )_) ._. Pretreating_NNP the_DT cells_NNS with_IN PTX_NNP (_( 100_CD ng_NN /_NN ml_NN )_) ,_, or_CC
          the_DT specific_JJ δ-_NN OR_NNP antagonist_NN ,_, naltrindole_NN (_( 10_CD μM_NN )_) ,_,
          completely_RB blocked_VBD the_DT DSEET-induced_NNP increase_NN in_IN ERK_NNP
          phosphorylation_NN (_( Figure_NN 1_CD b_SYM )_) ._. These_DT results_NNS suggest_VBP that_IN
          DSLET_NNP utilizes_NNS a_DT G_NNP 
          i_NNP -_: coupled_VBN δ-_NN OR_NNP to_TO stimulate_VB ERK_NNP 1_CD and_CC
          2_CD ._. We_PRP then_RB took_VBD advantage_NN of_IN the_DT HEK-_NNP 293_CD cell_NN line_NN 's_POS
          endogenous_JJ expression_NN of_IN the_DT EGFR_NNP to_TO examine_VB this_DT
          receptor_NN 's_POS ability_NN to_TO activate_VBP ERKs_NNP ._. Similar_JJ to_TO DSLET_NNP ,_,
          EGF_NNP (_( 5_CD ng_NN /_NN ml_NN )_) produces_VBZ a_DT robust_JJ activation_NN of_IN ERKs_NNP in_IN
          δ-_NN OR-expressing_NNP HEK-_NNP 293_CD cells_NNS after_IN a_DT 5_CD minute_NN treatment_NN
          (_( Figure_NN 2_CD a_DT )_) ._. PTX_NNP did_VBD not_RB attenuate_NN EGF-mediated_NNP ERK_NNP
          activation_NN (_( Figure_NN 2_CD a_DT )_) ,_, although_IN this_DT response_NN was_VBD
          completely_RB blocked_VBN by_IN the_DT EGFR_NNP kinase_NN inhibitor_NN ,_, AG_NNP 1478_CD
          (_( 1_CD μM_NN )_) (_( Figure_NN 2_CD a_DT )_) ._. Conversely_RB ,_, DSLET-induced_NNP ERK_NNP
          activation_NN was_VBD unaffected_JJ by_IN AG_NNP 1478_CD ,_, suggesting_VBG that_IN
          different_JJ tyrosine_NN kinases_NNS are_VBP involved_VBN in_IN opioid-_NN and_CC
          EGF-dependent_NNP MAPK_NNP activity_NN (_( Figure_NN 2_CD b_SYM )_) ._. DSLET-mediated_NNP
          ERK_NNP activation_NN was_VBD significantly_RB inhibited_VBD by_IN the_DT Src_NNP
          kinase_NN inhibitor_NN ,_, PP_NNP 1_CD (_( 10_CD μM_NN )_) (_( Figure_NN 3_LS )_) ._. PP_NNP 1_CD also_RB had_VBD a_DT
          significant_JJ inhibitory_NN (_( 75_CD %_NN reduction_NN )_) effect_NN on_IN MAPK_NNP
          activation_NN by_IN EGF_NNP (_( Figure_NN 3_LS )_) ._.
        
        
          DSLET-induced_NNP ERK_NNP activation_NN does_VBZ not_RB produce_VB
          hyper-phosphorylation_JJ of_IN the_DT EGFR_NNP
          Our_PRP$ next_JJ experiments_NNS were_VBD designed_VBN to_TO examine_VB whether_IN
          the_DT EGFR_NNP becomes_VBZ tyrosine_NN phosphorylated_JJ during_IN ERK_NNP
          activation_NN by_IN DSLET_NNP ._. As_IN stated_VBN in_IN the_DT introduction_NN ,_,
          several_JJ GPCRs_NNP (_( including_VBG the_DT EPAR_NNP ,_, β_NN 
          2_CD -_: AR_NNP ,_, and_CC substance_NN P_NN (_( SP-R_NNP )_) )_) [_NN 14_CD 18_CD
          19_CD 20_CD ]_NN increase_NN EGFR_NNP phosphorylation_NN during_IN the_DT course_NN
          of_IN ERK_NNP activation_NN ,_, and_CC it_PRP is_VBZ believed_VBN ,_, that_IN in_IN these_DT
          instances_NNS ,_, this_DT event_NN is_VBZ an_DT initial_JJ step_NN in_IN the_DT
          progression_NN of_IN the_DT MAPK_NNP cascade_NN ._. Our_PRP$ laboratory_NN has_VBZ
          previously_RB reported_VBN [_NN 11_CD 13_CD ]_NN that_IN 5_CD -_: opioids_NNS induce_VB
          tyrosine_NN phosphorylation_NN of_IN the_DT δ-_NN OR_NNP ,_, and_CC it_PRP appears_VBZ that_IN
          this_DT is_VBZ catalyzed_JJ by_IN the_DT non-receptor_JJ tyrosine_NN kinase_NN
          Src_NNP ._. However_RB ,_, transphosphorylation_NN of_IN the_DT EGFR_NNP after_IN OR_NNP
          activation_NN has_VBZ not_RB been_VBN reported_VBN ._. WT-δ-OR-expressing_NNP
          HEK-_NNP 293_CD cells_NNS were_VBD exposed_VBN to_TO increasing_VBG concentrations_NNS
          of_IN either_DT DSLET_NNP (_( 1_CD -_: 1000_CD nM_NN )_) or_CC EGF_NNP (_( 0_CD ._. 1_LS -_: 100_CD ng_NN /_NN ml_NN )_) for_IN
          five_CD minutes_NNS to_TO induce_VB ERK_NNP activation_NN ._. As_IN stated_VBN earlier_RBR ,_,
          either_CC DSLET_NNP or_CC EGF_NNP increased_VBD the_DT appearance_NN of_IN
          phosphorylated_JJ ERK_NNP in_IN a_DT time_NN and_CC concentration_NN dependent_JJ
          manner_NN ._. A_DT portion_NN of_IN the_DT lysates_NNS used_VBN to_TO measure_VB ERK_NNP
          activation_NN was_VBD used_VBN to_TO immunoprecipitate_NN the_DT EGFR_NNP or_CC δ-_NN OR_NNP
          to_TO determine_VB their_PRP$ degree_NN of_IN tyrosine_NN phosphorylation_NN ._.
          After_IN immunoprecipitation_NN of_IN the_DT FLAG-tagged_NNP δ-_NN OR_NNP or_CC the_DT
          EGFR_NNP with_IN the_DT appropriate_JJ antibodies_NNS ,_, we_PRP found_VBD that_IN only_RB
          DSLET_NNP induced_VBD tyrosine_NN phosphorylation_NN of_IN the_DT δ-_NN OR_NNP ,_,
          whereas_IN only_RB EGF_NNP potentiated_JJ EGFR_NNP phosphorylation_NN (_( Figure_NN
          4_LS )_) ._. 1_LS μM_NN DSLET-induced_NNP tyrosine_NN phosphorylation_NN of_IN the_DT
          δ-_NN OR_NNP was_VBD inhibited_VBD by_IN naltrindole_NN ,_, PP_NNP 1_CD ,_, but_CC not_RB by_IN AG_NNP 1478_CD
          (_( Figure_NN 5_LS )_) ._. These_DT results_NNS suggest_VBP that_DT transactivation_NN of_IN
          the_DT EGFR_NNP does_VBZ not_RB play_VB a_DT role_NN in_IN δ-_NN OR_NNP phosphorylation_NN or_CC
          ERK_NNP activation_NN by_IN δ-opioids_JJ ._.
        
        
          Determining_VBG whether_IN a_DT co-expressed_JJ RTK_NNP is_VBZ
          structurally_RB necessary_JJ for_IN δ-_NN OR-mediated_NNP ERK_NNP
          activation_NN
          
            EGFR_NNP down-regulation_JJ does_VBZ not_RB affect_VB
            DSLET-mediated_NNP ERK_NNP activation_NN in_IN HEK-_NNP 293_CD cells_NNS
            Despite_IN the_DT lack_NN of_IN direct_JJ evidence_NN that_IN DSLET_NNP
            induces_VBZ the_DT transactivation_NN of_IN co-expressed_JJ RTKs_NNP ,_, it_PRP is_VBZ
            possible_JJ that_IN the_DT EGFR_NNP ,_, in_IN some_DT way_NN ,_, contributes_VBZ to_TO ERK_NNP
            activation_NN by_IN opioids_NNS ._. It_PRP is_VBZ possible_JJ that_IN RTKs_NNP and_CC
            GPCRs_NNP share_NN important_JJ protein_NN intermediates_NNS that_WDT are_VBP
            required_VBN during_IN ERK_NNP activation_NN ._. Therefore_RB ,_, we_PRP wished_VBD to_TO
            determine_VB what_WP effects_NNS the_DT down-regulation_JJ of_IN the_DT EGFR_NNP
            would_MD have_VB on_IN ERK_NNP signalling_VBG via_IN the_DT δ-_NN OR_NNP ._. HEK-_NNP 293_CD
            cells_NNS expressing_VBG the_DT WT-δ-OR_NNP were_VBD exposed_VBN to_TO EGF_NNP (_( 100_CD
            ng_NN /_NN ml_NN )_) for_IN 24_CD hours_NNS in_IN order_NN to_TO down-regulate_JJ and_CC
            desensitize_NN the_DT endogenous_JJ EGFR_NNP ._. After_IN chronic_JJ EGF_NNP
            treatment_NN ,_, the_DT cultures_NNS were_VBD washed_VBN with_IN serum-free_JJ
            media_NNS and_CC then_RB exposed_VBN acutely_RB (_( 5_CD minutes_NNS )_) to_TO either_CC
            EGF_NNP (_( 10_CD ng_NN /_NN ml_NN )_) or_CC DSLET_NNP (_( 1_CD μM_NN )_) to_TO stimulate_VB ERK_NNP
            phosphorylation_NN ._. In_IN EGF_NNP pre-treated_JJ cultures_NNS ,_, acute_JJ EGF_NNP
            (_( 10_CD ng_NN /_NN ml_NN )_) was_VBD unable_JJ to_TO increase_VB the_DT expression_NN of_IN
            phospho-_NN ERKs_NNP compared_VBD to_TO media-exposed_JJ controls_NNS (_( Figure_NN
            6_CD )_) ._. This_DT lack_NN of_IN response_NN appears_VBZ to_TO be_VB due_JJ to_TO the_DT
            down-regulation_JJ of_IN EGFRs_NNP from_IN these_DT cells_NNS as_IN confirmed_VBN
            by_IN immunoblots_NNS using_VBG the_DT anti-_NN EGFR_NNP antibody_NN (_( data_NNS not_RB
            shown_VBN )_) ._. However_RB ,_, DSLET-mediated_NNP ERK_NNP activation_NN was_VBD
            unaltered_JJ in_IN identically_RB pretreated_JJ cultures_NNS ._.
            In_IN cells_NNS pretreated_JJ with_IN DSLET_NNP (_( 10_CD μM_NN ;_: 24_CD hours_NNS )_) to_TO
            induce_VB down-regulation_JJ of_IN δ-_NN ORs_NNP [_NN 21_CD ]_NN ,_, DSLET_NNP (_( 1_CD μM_NN )_)
            was_VBD no_DT longer_RB able_JJ to_TO activate_VBP the_DT ERK_NNP cascade_NN ,_, but_CC the_DT
            ERK_NNP response_NN to_TO acute_JJ EGF_NNP (_( 10_CD ng_NN /_NN ml_NN )_) was_VBD unchanged_JJ
            compared_VBN to_TO medium-treated_JJ controls_NNS (_( Figure_NN 6_CD )_) ._. These_DT
            results_NNS indicate_VBP that_IN a_DT reduction_NN in_IN the_DT function_NN and_CC
            density_NN of_IN endogenous_JJ EGFRs_NNP has_VBZ little_JJ effect_NN on_IN
            opioid-mediated_JJ MAPK_NNP cascades_NNS ,_, and_CC suggests_VBZ that_IN the_DT
            enzyme_NN cascades_NNS that_WDT control_NN δ-_NN OR-_NNP and_CC EGFR-mediated_NNP
            ERK_NNP activation_NN are_VBP separate_JJ ._.
          
          
            DSLET_NNP activates_NNS ERK_NNP even_RB in_IN a_DT cell_NN line_NN devoid_JJ of_IN
            the_DT EGFR_NNP
            C_NNP 6_CD glioma_NN cells_NNS have_VBP been_VBN used_VBN as_IN host_NN cells_NNS for_IN the_DT
            transfection_NN of_IN several_JJ GPCR_NNP types_NNS ,_, and_CC have_VBP the_DT
            advantage_NN of_IN expressing_VBG high_JJ levels_NNS of_IN ERK_NNP ,_, while_IN being_VBG
            devoid_JJ of_IN the_DT EGFR_NNP ._. In_IN C_NNP 6_CD glioma_NN cells_NNS that_WDT express_VBP the_DT
            mouse_NN δ-_NN OR_NNP ,_, DSLET_NNP produced_VBD a_DT concentration-dependent_JJ
            increase_NN in_IN the_DT appearance_NN of_IN phospho-_NN ERK_NNP 1_CD and_CC 2_CD ._.
            DSLET-mediated_NNP ERK_NNP activation_NN in_IN C_NNP 6_CD -_: δ-_NN OR_NNP cells_NNS was_VBD
            completely_RB inhibited_VBD by_IN either_DT pre-treatment_JJ with_IN PTX_NNP
            or_CC naltrindole_NN (_( data_NNS not_RB shown_VBN )_) ._. In_IN contrast_NN ,_, EGF_NNP was_VBD
            unable_JJ to_TO elicit_NN ERK_NNP activation_NN ,_, at_IN any_DT concentration_NN
            tested_VBD ,_, up_IN to_TO 1_CD μM_NN (_( Figure_NN 7_CD )_) ._. Furthermore_RB ,_, the_DT EGFR_NNP
            antagonist_NN ,_, AG_NNP 1478_CD ,_, had_VBD no_DT effect_NN on_IN DSLET-mediated_NNP ERK_NNP
            activation_NN ,_, which_WDT eliminated_VBD the_DT possibility_NN that_IN these_DT
            antagonists_NNS produced_VBD non-specific_JJ ,_, inhibitory_NN effects_NNS
            (_( Figure_NN 7_CD )_) ._.
          
          
            Potential_JJ of_IN endogenously_RB expressed_VBD insulin_NN
            receptors_NNS (_( IR_NNP )_) and_CC PDGFR_NNP to_TO act_VB as_IN surrogate_JJ protein_NN
            scaffolds_NNS during_IN ERK_NNP activation_NN by_IN δ-opioids_JJ
            However_RB ,_, C_NNP 6_CD glioma_NN cells_NNS express_VBP additional_JJ RTKs_NNP
            including_VBG insulin_NN (_( IR_NNP )_) and_CC platelet-derived_JJ growth_NN
            factor_NN (_( PDGFR_NNP )_) receptors_NNS ._. It_PRP is_VBZ possible_JJ that_IN these_DT
            sites_NNS can_MD be_VB used_VBN as_IN surrogate_JJ scaffold_NN proteins_NNS during_IN
            ERK_NNP activation_NN ,_, and_CC we_PRP explored_JJ the_DT possibility_NN that_IN
            δ-opioids_JJ induce_VB the_DT transphosphorylation_NN of_IN these_DT two_CD
            RTKs_NNP ._. At_IN concentrations_NNS of_IN 10_CD μM_NN ,_, neither_DT DSLET_NNP ,_, DADLE_NNP ,_,
            nor_CC DPDPE_NNP were_VBD found_VBN to_TO increase_VB the_DT tyrosine_NN
            phosphorylation_NN of_IN the_DT IR_NNP or_CC the_DT PDGFR_NNP ,_, whereas_IN insulin_NN
            (_( 100_CD ng_NN /_NN ml_NN )_) or_CC PDGF_NNP (_( 50_CD ng_NN /_NN ml_NN )_) induced_VBN significant_JJ
            tyrosine_NN phosphorylation_NN of_IN these_DT sites_NNS (_( Figure_NN 8_CD )_) ._.
            Moreover_RB ,_, we_PRP pre-treated_JJ C_NNP 6_CD -_: δ-_NN OR_NNP cells_NNS with_IN the_DT IR_NNP
            antagonist_NN ,_, hydroxy-_NN 2_CD -_: napthalenylmethylphosphonic_JJ
            acid-tris_JJ acetoxymethylester_NN (_( HNMPA-_NNP (_( AM_NNP )_) 
            3_CD ;_: 100_CD μM_NN )_) ,_, or_CC the_DT PDGFR_NNP
            antagonist_NN ,_, (_( tyrosphostin_NN 9_CD ;_: 100_CD μM_NN )_) before_IN the_DT
            addition_NN of_IN DSLET_NNP (_( 1_CD μM_NN )_) ._. Despite_IN the_DT presence_NN of_IN these_DT
            catalytic_JJ RTK_NNP inhibitors_NNS ,_, δ-opioid-mediated_JJ ERK_NNP
            activation_NN was_VBD not_RB significantly_RB altered_VBN in_IN comparison_NN
            to_TO untreated_JJ cultures_NNS (_( Figure_NN 9_CD )_) ._. Furthermore_RB ,_,
            immunoprecipitation_NN of_IN the_DT δ-_NN OR_NNP ,_, followed_VBN by_IN
            immunoblotting_VBG using_VBG anti-phosphotyrosine_JJ antibodies_NNS ,_,
            revealed_VBD that_IN these_DT inhibitors_NNS did_VBD not_RB attenuate_NN
            tyrosine_NN phosphorylation_NN of_IN δ-_NN ORs_NNP after_IN DSLET_NNP treatment_NN
            (_( Figure_NN 9_CD )_) ._. The_DT results_NNS presented_VBN ,_, herein_NN ,_, strongly_RB
            suggest_VBP that_DT transactivation_NN of_IN RTKs_NNP does_VBZ not_RB make_VB a_DT
            significant_JJ contribution_NN to_TO DSLET-induced_NNP ERK_NNP
            activation_NN in_IN at_IN least_JJS two_CD different_JJ cell_NN lines_NNS ._.
          
        
      
      
        Discussion_NNP
        With_IN the_DT first_JJ evidence_NN that_IN GPCRs_NNP could_MD signal_VB via_IN the_DT
        MAPK_NNP cascade_NN ,_, many_JJ investigators_NNS have_VBP looked_VBN for_IN a_DT common_JJ
        mechanism_NN of_IN activation_NN that_WDT could_MD be_VB applied_VBN across_IN
        receptor_NN types_NNS ._. Unlike_IN the_DT better_RBR understood_VBN mechanism_NN
        whereby_WRB single-transmembrane_JJ RTKs_NNP (_( e_SYM ._. g_SYM ._. EGFR_NNP ,_, IR_NNP ,_, or_CC PDGFR_NNP )_)
        stimulate_VB ERKs_NNP [_NN 22_CD 23_CD ]_NN ,_, no_DT single_JJ sequence_NN of_IN events_NNS
        appears_VBZ to_TO hold_VB among_IN GPCRs_NNP ,_, even_RB when_WRB they_PRP are_VBP expressed_VBN
        in_IN the_DT same_JJ cell_NN line_NN ._. For_IN instance_NN ,_, studies_NNS from_IN two_CD
        laboratories_NNS reported_VBD marked_VBN differences_NNS in_IN the_DT way_NN the_DT β_NN 
        2_CD -_: adrenergic_JJ receptor_NN (_( β_NN 
        2_CD -_: AR_NNP )_) activates_NNS ERK_NNP 1_CD and_CC 2_CD in_IN HEK-_NNP 293_CD
        cells_NNS ._. In_IN one_CD study_NN ,_, the_DT β_NN 
        2_CD -_: AR_NNP activates_NNS ERK_NNP through_IN it_PRP 's_VBZ
        coupling_NN to_TO a_DT PTX-sensitive_NNP G_NNP 
        i_NNP protein_NN and_CC subsequent_JJ Ras_NNP activation_NN
        [_NN 24_CD ]_NN ,_, while_IN ,_, in_IN another_DT ,_, ERK_NNP phosphorylation_NN occurred_VBD in_IN
        a_DT PTX-independent_NNP and_CC a_DT G_NNP 
        s_VBZ -_: and_CC cAMP-dependent_JJ fashion_NN [_NN 25_CD ]_NN ._.
        Furthermore_RB ,_, these_DT studies_NNS indicate_VBP that_IN the_DT same_JJ receptor_NN
        may_MD activate_VBP ERKs_NNP via_IN one_CD mechanism_NN when_WRB it_PRP is_VBZ endogenously_RB
        expressed_VBN and_CC via_IN another_DT when_WRB it_PRP is_VBZ transfected_JJ into_IN a_DT
        cell_NN line_NN [_NN 25_CD ]_NN ._.
        Despite_IN numerous_JJ reported_VBD differences_NNS ,_, it_PRP does_VBZ appear_VB
        that_IN diverse_JJ GPCRs_NNP share_NN common_JJ mechanistic_JJ themes_NNS during_IN
        ERK_NNP stimulation_NN ,_, including_VBG the_DT tyrosine-phosphorylation_JJ of_IN
        Shc_NNP and_CC its_PRP$ complexing_VBG with_IN Grb_NNP 2_CD ,_, mSOS_NN recruitment_NN ,_, the_DT
        GTP-loading_NNP of_IN Ras_NNP ,_, and_CC Raf-_NNP 1_CD activation_NN leading_VBG to_TO MEK-_NNP 1_CD
        phosphorylation_NN [_NN 1_CD ]_NN ._. However_RB ,_, the_DT progression_NN of_IN each_DT of_IN
        these_DT downstream_JJ events_NNS after_IN GPCR_NNP stimulation_NN depends_VBZ
        first_JJ on_IN the_DT tyrosine_NN phosphorylation_NN of_IN a_DT membrane-bound_JJ
        protein_NN that_WDT will_MD be_VB used_VBN as_IN a_DT scaffold_NN ,_, which_WDT will_MD bind_NN
        the_DT other_JJ proteins_NNS (_( e_SYM ._. g_SYM ._. Shc_NNP ,_, Grb_NNP 2_CD ,_, Gab_NNP 1_CD ,_, mSOS_NN ._. ._. ._. ._. etc_FW ._. ._. ._. )_)
        [_NN 7_CD ]_NN ._. Moreover_RB ,_, the_DT exact_JJ identity_NN of_IN the_DT tyrosine_NN
        kinase_NN (_( s_VBZ )_) involved_VBN in_IN this_DT initial_JJ step_NN appears_VBZ to_TO vary_VB
        among_IN receptor_NN types_NNS ,_, with_IN RTKs_NNP ,_, non-receptor_JJ protein_NN
        tyrosine_NN kinases_NNS (_( PTKs_NNP )_) ,_, or_CC FAKs_NNP being_VBG involved_VBN in_IN
        particular_JJ instances_NNS [_NN 26_CD ]_NN ._.
        In_IN this_DT report_NN ,_, we_PRP questioned_VBD whether_IN the_DT EGFR_NNP acts_NNS as_IN a_DT
        surrogate_JJ scaffold_NN during_IN ERK_NNP activation_NN through_IN the_DT δ-_NN OR_NNP ,_,
        as_IN it_PRP appears_VBZ to_TO do_VB for_IN several_JJ other_JJ GPCRs_NNP [_NN 7_CD ]_NN ._. To_TO act_VB
        as_IN a_DT surrogate-binding_JJ site_NN for_IN complex_JJ formation_NN ,_, the_DT
        literature_NN states_NNS that_IN this_DT protein_NN must_MD first_RB become_VB
        tyrosine-phosphorylated_JJ [_NN 7_CD ]_NN ._. Tyrosine_NNP phosphorylation_NN of_IN
        the_DT EGFR_NNP is_VBZ apparent_JJ after_IN agonist_NN stimulation_NN of_IN the_DT α_NN 
        2_CD -_: AR_NNP (_( COS-_NNP 7_CD )_) ,_, β_NN 
        2_CD -_: AR_NNP (_( COS-_NNP 7_CD )_) ,_, insulin-like_JJ growth_NN
        factor_NN (_( IGF-_NNP 1_CD ;_: COS-_NNP 7_CD )_) ,_, substance_NN P_NN ,_, and_CC the_DT
        lysophosphatidic_JJ acid_NN receptor_NN (_( LPAR_NNP )_) [_NN 7_CD ]_NN ._. In_IN addition_NN ,_,
        each_DT of_IN the_DT aforementioned_JJ ligands_NNS also_RB increases_VBZ ERK_NNP
        phosphorylation_NN when_WRB the_DT proper_JJ receptor_NN is_VBZ expressed_VBN in_IN
        these_DT cell_NN lines_NNS ._. ERK_NNP activation_NN and_CC EGFR_NNP phosphorylation_NN
        via_IN each_DT of_IN these_DT receptors_NNS was_VBD inhibited_VBD by_IN prior_JJ exposure_NN
        to_TO the_DT EGFR_NNP kinase_NN inhibitor_NN ,_, AG_NNP 1478_CD ._.
        However_RB ,_, the_DT Src_NNP inhibitor_NN ,_, PP_NNP 1_CD or_CC the_DT expression_NN of_IN a_DT
        dominant-negative_JJ Src_NNP mutant_JJ ,_, will_MD reduce_VB GPCR-mediated_NNP
        transphosphorylation_NN of_IN the_DT EGFR_NNP and_CC GPCR-mediated_NNP ERK_NNP
        activation_NN to_TO varying_VBG degrees_NNS (_( partial_JJ to_TO total_VB )_) ,_,
        suggesting_VBG that_IN at_IN least_JJS two_CD different_JJ tyrosine_NN kinases_NNS can_MD
        be_VB involved_VBN [_NN 18_CD ]_NN ._. Src_NNP was_VBD found_VBN to_TO co-immunoprecipitate_JJ
        with_IN the_DT phosphorylated_JJ EGFR_NNP in_IN COS-_NNP 7_CD cells_NNS exposed_VBN to_TO
        either_CC LPA_NNP or_CC EGF_NNP [_NN 14_CD ]_NN ._. These_DT authors_NNS reported_VBD that_IN the_DT
        autophosphorylation_NN of_IN Y_NNP 350_CD in_IN the_DT EGFR_NNP does_VBZ not_RB occur_VB
        after_IN LPA_NNP exposure_NN ,_, suggesting_VBG that_DT c-_NN Src_NNP is_VBZ the_DT principal_JJ
        tyrosine_NN kinase_NN in_IN this_DT instance_NN and_CC not_RB the_DT EGFR_NNP 's_POS
        intrinsic_JJ tyrosine_NN kinase_NN ._. Src_NNP has_VBZ also_RB been_VBN found_VBN to_TO
        co-immunoprecipitate_JJ with_IN the_DT agonist-stimulated_JJ β_NN 
        2_CD -_: AR_NNP during_IN the_DT period_NN of_IN ERK_NNP
        activation_NN [_NN 8_CD ]_NN ._. Our_PRP$ previous_JJ work_NN [_NN 11_CD 13_CD ]_NN suggested_VBD
        that_IN a_DT Src-like_NNP protein_NN tyrosine_NN kinase_NN was_VBD primarily_RB
        responsible_JJ for_IN tyrosine_NN phosphorylation_NN of_IN the_DT δ-_NN OR_NNP and_CC
        ERK_NNP activation_NN induced_VBN by_IN DTLET_NNP when_WRB the_DT receptor_NN was_VBD
        expressed_VBN in_IN CHO_NNP or_CC HEK-_NNP 293_CD cells_NNS ,_, because_IN both_DT responses_NNS
        were_VBD blocked_VBN by_IN the_DT presence_NN of_IN 50_CD μM_NN PP_NNP 1_CD ._. The_DT seemingly_RB
        dominant_JJ role_NN of_IN Src_NNP in_IN opioid-mediated_JJ ERK_NNP stimulation_NN is_VBZ
        strengthened_VBN in_IN the_DT present_JJ report_NN because_IN of_IN considerable_JJ
        evidence_NN that_IN the_DT EGFR_NNP antagonist_NN ,_, AG_NNP 1478_CD ,_, was_VBD unable_JJ to_TO
        reduce_VB DSLET-mediated_NNP ERK_NNP activation_NN ._. This_DT suggests_VBZ that_IN
        the_DT EGFR_NNP has_VBZ minimal_JJ ,_, if_IN any_DT ,_, involvement_NN in_IN the_DT
        opioid-activated_JJ ERK_NNP cascade_NN ._. It_PRP is_VBZ possible_JJ ,_, that_IN the_DT dual_JJ
        coupling_NN of_IN the_DT LPAR_NNP to_TO both_DT inhibitory_NN (_( G_NNP 
        i_NNP )_) and_CC stimulatory_NN (_( G_NNP 
        12_CD /_NN 13_CD and_CC G_NNP 
        q_NN )_) G_NNP proteins_NNS is_VBZ a_DT reason_NN for_IN these_DT
        differences_NNS ._.
        In_IN this_DT report_NN ,_, we_PRP have_VBP presented_VBN considerable_JJ evidence_NN
        that_DT δ-_NN ORs_NNP and_CC EGFRs_NNP activate_VBP ERKs_NNP ,_, independently_RB ,_, without_IN
        the_DT need_NN for_IN transphosphorylation_NN of_IN a_DT co-expressed_JJ RTK_NNP ._. We_PRP
        used_VBD C_NNP 6_CD glioma_NN cells_NNS ,_, transfected_JJ to_TO stably_RB express_VB the_DT
        mouse_NN δ-_NN OR_NNP ,_, to_TO examine_VB ERK_NNP activation_NN by_IN δ-opioids_JJ in_IN a_DT
        line_NN that_WDT does_VBZ not_RB express_VB the_DT EGFR_NNP to_TO confirm_VB our_PRP$ results_NNS
        obtained_VBN in_IN the_DT receptor_NN down-regulation_JJ experiments_NNS ._. We_PRP
        observed_VBD that_IN DSLET_NNP activated_VBN p_NN 42_CD mapkand_NN p_NN 44_CD mapkvery_NN
        robustly_RB in_IN this_DT cell_NN line_NN ._. C_NNP 6_CD glioma_NN cells_NNS do_VBP express_VB
        growth_NN factor_NN receptors_NNS that_WDT bind_NN PDGF_NNP and_CC insulin_NN ._.
        However_RB ,_, neither_DT of_IN these_DT proteins_NNS has_VBZ been_VBN reported_VBN to_TO act_VB
        as_IN a_DT surrogate_JJ scaffold_NN during_IN ERK_NNP activation_NN by_IN non-opioid_JJ
        GPCRs_NNP [_NN 27_CD ]_NN ._. In_IN the_DT present_JJ report_NN ,_, DSLET-mediated_NNP ERK_NNP
        phosphorylation_NN was_VBD unaltered_JJ by_IN the_DT presence_NN of_IN the_DT IR_NNP or_CC
        PDGFR_NNP antagonists_NNS ,_, HNMPA-_NNP (_( AM_NNP )_) 
        3_CD and_CC tyrosphostin_NN 9_CD ,_, respectively_RB ._. It_PRP
        is_VBZ probable_JJ that_IN the_DT δ-_NN OR_NNP in_IN C_NNP 6_CD glioma_NN cells_NNS also_RB acts_VBZ as_IN
        its_PRP$ own_JJ platform_NN for_IN the_DT binding_JJ of_IN Shc_NNP ,_, etc_FW ._. ,_, since_IN the_DT
        δ-_NN OR_NNP also_RB undergoes_NNS agonist-mediated_JJ tyrosine_NN
        phosphorylation_NN in_IN this_DT particular_JJ cell_NN line_NN (_( Kramer_NNP et_CC
        al_NN ._. ,_, unpublished_JJ observations_NNS )_) ,_, similar_JJ to_TO what_WP we_PRP
        previously_RB reported_VBD for_IN the_DT δ-_NN OR_NNP expressed_VBD in_IN Chinese_JJ
        hamster_NN ovary_JJ or_CC HEK-_NNP 293_CD cells_NNS [_NN 11_CD 13_CD ]_NN ._. Thus_RB ,_, in_IN at_IN
        least_JJS two_CD different_JJ cell_NN lines_NNS ,_, HEK-_NNP 293_CD and_CC C_NNP 6_CD glioma_NN ,_, we_PRP
        have_VBP significant_JJ evidence_NN that_DT transactivation_NN of_IN an_DT
        endogenously_RB expressed_VBN RTK_NNP is_VBZ not_RB required_VBN for_IN ERK_NNP
        activation_NN through_IN opioid_NN receptors_NNS ._.
        While_IN the_DT EGFR_NNP does_VBZ not_RB appear_VB to_TO be_VB phosphorylated_JJ
        during_IN DSLET-mediated_NNP ERK_NNP activation_NN ,_, it_PRP is_VBZ possible_JJ that_IN
        the_DT EGFR_NNP is_VBZ somehow_RB involved_VBN in_IN this_DT response_NN when_WRB it_PRP is_VBZ
        present_JJ ._. Buist_NNP et_CC al_NN ._. ,_, [_NN 27_CD ]_NN reported_VBD that_IN
        endogenously-expressed_JJ LPA_NNP and_CC endothelin-_NN 1_CD (_( ET-_NNP 1_LS )_)
        receptors_NNS in_IN SK-N-MC_NNP cells_NNS do_VBP not_RB activate_VBP ERKs_NNP unless_IN the_DT
        EGFR_NNP is_VBZ co-expressed_JJ ,_, although_IN each_DT GPCR_NNP is_VBZ functional_JJ as_IN
        evidenced_VBN by_IN their_PRP$ ability_NN to_TO increase_VB intracellular_NN [_NN Ca_MD
        2_CD +_NN ]_NN ._. In_IN the_DT presence_NN of_IN the_DT EGFR_NNP ,_, ligand_NN activation_NN of_IN LPA_NNP
        and_CC ET-_NNP 1_CD receptors_NNS did_VBD not_RB increase_VB EGFR_NNP phosphorylation_NN
        even_RB though_IN both_DT the_DT LPA_NNP and_CC ET-_NNP 1_CD receptors_NNS stimulated_VBN ERK_NNP
        activity_NN by_IN 10_CD -_: fold_VB over_IN basal_NN [_NN 27_CD ]_NN ._. Specifically_RB ,_, key_JJ
        protein_NN intermediates_NNS may_MD be_VB physically_RB associated_VBN with_IN
        endogenous_JJ RTKs_NNP in_IN HEK-_NNP 293_CD cells_NNS ,_, and_CC therefore_RB ,_,
        down-regulation_JJ of_IN the_DT EGFR_NNP may_MD negatively_RB affect_VB ERK_NNP
        phosphorylation_NN by_IN opioids_NNS ._. To_TO examine_VB this_DT ,_, we_PRP induced_VBD
        significant_JJ down-regulation_JJ of_IN EGFR_NNP density_NN and_CC function_NN by_IN
        exposing_VBG δ-_NN OR-HEK-_NNP 293_CD cells_NNS to_TO 100_CD ng_NN /_NN ml_NN EGF_NNP for_IN 24_CD hours_NNS ._.
        Functionally_NNP ,_, these_DT cells_NNS are_VBP no_DT longer_RB capable_JJ of_IN
        activating_VBG ERK_NNP 1_CD or_CC 2_CD in_IN response_NN to_TO 10_CD ng_NN /_NN ml_NN EGF_NNP (_( Figure_NN )_) ,_,
        whereas_IN this_DT concentration_NN produces_VBZ a_DT strong_JJ effect_NN in_IN
        non-pretreated_JJ cells_NNS ._. Conversely_RB ,_, DSLET-mediated_NNP ERK_NNP
        phosphorylation_NN is_VBZ actually_RB greater_JJR in_IN chronically-treated_JJ
        EGF_NNP cultures_NNS to_TO that_DT observed_VBD in_IN cells_NNS not_RB previously_RB
        exposed_VBN to_TO high_JJ EGF_NNP concentrations_NNS ._. This_DT may_MD represent_VB a_DT
        compensatory_JJ effect_NN to_TO counteract_VB the_DT loss_NN of_IN function_NN of_IN
        an_DT important_JJ growth_NN factor_NN receptor_NN ._. In_IN a_DT similar_JJ
        experiment_NN ,_, a_DT 24_CD -_: hour_NN exposure_NN to_TO DSLET_NNP (_( 10_CD μM_NN )_) induced_VBN
        significant_JJ δ-_NN OR_NNP down-regulation_JJ and_CC an_DT almost_RB complete_JJ
        loss_NN of_IN DSLET-mediated_NNP ERK_NNP phosphorylation_NN ._. MAP_NNP kinase_NN
        activation_NN by_IN a_DT 5_CD minute_NN exposure_NN to_TO EGF_NNP was_VBD unaffected_JJ by_IN
        δ-_NN OR_NNP down-regulation_JJ ._. These_DT results_NNS ,_, taken_VBN together_RB ,_,
        suggest_VBP that_IN GPCRs_NNP and_CC RTKs_NNP can_MD act_VB as_IN independent_JJ
        regulators_NNS of_IN MAP_NNP kinase_NN cascades_NNS ,_, although_IN interactions_NNS
        between_IN the_DT two_CD receptor_NN types_NNS may_MD exist_VB in_IN certain_JJ
        cases_NNS ._.
        In_IN conclusion_NN ,_, we_PRP report_VBP that_IN the_DT δ-_NN OR_NNP agonist_NN ,_, DSLET_NNP ,_,
        induces_VBZ significant_JJ ERK_NNP activation_NN in_IN the_DT absence_NN of_IN any_DT
        increase_NN in_IN phosphorylation_NN of_IN the_DT co-expressed_JJ EGFR_NNP in_IN
        HEK-_NNP 293_CD cells_NNS ._. HEK-_NNP 293_CD cells_NNS endogenously_RB express_VBP the_DT EGFR_NNP ,_,
        and_CC EGF_NNP produces_VBZ robust_JJ ERK_NNP activation_NN concomitant_NN with_IN
        EGFR_NNP tyrosine_NN phosphorylation_NN ._. Immunoprecipitation_NNP studies_NNS
        showed_VBD that_IN the_DT δ-_NN OR_NNP becomes_VBZ tyrosine_NN phosphorylated_JJ after_IN
        exposure_NN to_TO DSLET_NNP ,_, but_CC not_RB to_TO EGF_NNP ._. These_DT studies_NNS were_VBD
        repeated_VBN in_IN δ-_NN OR-transfected_NNP C_NNP 6_CD glioma_NN cells_NNS ,_, which_WDT do_VBP not_RB
        express_VB the_DT EGFR_NNP ._. In_IN these_DT cells_NNS ,_, DSLET_NNP was_VBD still_RB able_JJ to_TO
        induce_VB ERK_NNP activation_NN ._. Additional_JJ studies_NNS showed_VBD that_IN the_DT
        two_CD RTKs_NNP ,_, which_WDT are_VBP present_JJ in_IN C_NNP 6_CD glioma_NN cells_NNS ,_, IRs_NNP and_CC
        PDGFRs_NNP ,_, had_VBD no_DT apparent_JJ role_NN on_IN ERK_NNP activation_NN by_IN a_DT
        δ-opioid_JJ agonist_NN ._. Furthermore_RB ,_, inducing_VBG down-regulation_JJ of_IN
        either_DT the_DT EGFR_NNP or_CC δ-_NN OR_NNP by_IN chronic_JJ agonist_NN treatment_NN has_VBZ
        little_JJ effect_NN on_IN ERK_NNP activation_NN by_IN the_DT other_JJ receptor_NN in_IN
        HEK-_NNP 293_CD cells_NNS ,_, suggesting_VBG that_IN these_DT pathways_NNS are_VBP distinct_JJ ._.
        These_DT results_NNS demonstrate_VBP that_IN opioid-mediated_JJ ERK_NNP
        activation_NN occurs_VBZ independently_RB of_IN EGFR_NNP
        transphosphorylation_NN ,_, and_CC that_IN the_DT tyrosine-phosphorylated_JJ
        δ-_NN OR_NNP may_MD serve_VB as_IN the_DT primary_JJ scaffold_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Drugs_NNS and_CC compounds_NNS
          All_DT chemicals_NNS used_VBN for_IN these_DT studies_NNS were_VBD of_IN reagent_NN
          grade_NN and_CC obtained_VBN from_IN the_DT following_VBG sources_NNS ._. The_DT Src_NNP
          inhibitor_NN ,_, 4_CD -_: amino-_NN 5_CD -_: (_( 4_CD -_: methylphenyl_NN )_) -_: 7_CD -_: (_( t-butyl_JJ )_) pyrazolo_NN
          [_NN 3_CD ,_, 4_CD -_: d_SYM ]_NN pyrimidine_NN (_( PP_NNP 1_LS )_) ,_, was_VBD purchased_VBN from_IN Calbiochem_NNP
          (_( La_NNP Jolla_NNP ,_, CA_NNP )_) ._. The_DT EGFR_NNP antagonist_NN ,_, AG_NNP 1478_CD
          (_( 4_CD -_: (_( 3_CD -_: chloroanilino_NN )_) -_: 6_CD ,_, 7_CD -_: dimethoxyquinazoline_NN )_) ,_, the_DT
          insulin_NN receptor_NN antagonist_NN ,_,
          hydroxy-_NN 2_CD -_: napthalenylmethylphosphonic_JJ acid-tris_JJ
          acetoxymethylester_NN (_( HNMPA-_NNP (_( AM_NNP )_) 
          3_LS )_) ,_, and_CC the_DT PDGFR_NNP antagonist_NN ,_,
          tyrosphostin_NN ,_, 9_CD were_VBD purchased_VBN from_IN Biomol_NNP (_( Plymouth_NNP
          Meeting_VBG ,_, PA_NNP )_) ._. The_DT opioid_NN agonist_NN ,_,
          [_NN D-S_NNP er-_NN Leu-enkephalin-_NNP Thr_NNP (_( DSLET_NNP )_) ,_, was_VBD received_VBN from_IN the_DT
          National_NNP Institute_NNP of_IN Drug_NNP Abuse_NNP (_( NIDA_NNP ,_, Baltimore_NNP ,_, MD_NNP )_)
          and_CC the_DT antagonist_NN ,_, naltrindole_NN ,_, was_VBD purchased_VBN from_IN
          Research_NNP Biochemicals_NNP ,_, Inc_NNP ._. ,_, (_( Natick_NNP ,_, MA_NNP )_) ._. Pertussis_NNP
          toxin_NN (_( PTX_NNP )_) was_VBD purchased_VBN from_IN Sigma_NNP Chemical_NNP Co_NNP ._. (_( St_NNP ._.
          Louis_NNP ,_, MO_NNP )_) ._. Insulin_NNP was_VBD obtained_VBN from_IN University_NNP Hospital_NNP
          of_IN New_NNP York_NNP University_NNP and_CC PDGF_NNP was_VBD purchased_VBN from_IN Biomol_NNP
          (_( Plymouth_NNP Meeting_VBG ,_, PA_NNP )_) ._. All_DT other_JJ compounds_NNS were_VBD obtained_VBN
          from_IN the_DT sources_NNS listed_VBN under_IN the_DT individual_JJ methods_NNS ._.
        
        
          Cell_NNP transfection_NN and_CC culture_NN
          C_NNP 6_CD glioma_NN cells_NNS were_VBD stably_RB transfected_JJ with_IN the_DT cDNA_NN
          encoding_VBG the_DT epitope-tagged_JJ (_( FLAG_NNP )_) mouse_NN δ-opioid_JJ
          receptor_NN (_( C_NNP 6_CD -_: δOR_NN )_) and_CC were_VBD created_VBN in_IN our_PRP$ laboratory_NN
          using_VBG the_DT Flp-_NNP In_IN transfection_NN method_NN ._. HEK-_NNP 293_CD cells_NNS were_VBD
          transfected_JJ ,_, in_IN house_NN ,_, with_IN the_DT cDNA_NN encoding_VBG the_DT
          FLAG-tagged_NNP wild-type_JJ (_( HEK-δOR_NNP )_) mouse_NN δ-_NN OR_NNP ._. Complete_JJ
          methods_NNS for_IN the_DT stable_JJ transfection_NN of_IN HEK-_NNP 293_CD cells_NNS to_TO
          express_VB the_DT wild_JJ type_NN receptor_NN can_MD be_VB found_VBN in_IN a_DT previous_JJ
          report_NN [_NN 13_CD ]_NN ._. Both_DT cell_NN lines_NNS were_VBD seeded_VBN in_IN 6_CD -_: well_RB
          dishes_NNS at_IN an_DT initial_JJ cell_NN density_NN of_IN 1_CD ×_NN 10_CD 6_CD cells_NNS /_NN well_RB
          and_CC were_VBD maintained_VBN in_IN Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS medium_NN
          (_( DMEM_NNP ;_: GibcoBRL_NNP )_) supplemented_JJ with_IN 2_CD mM_NN L-_NNP glutamine_NN ,_, 5_CD %_NN
          fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) (_( Gemini_NNP Bio-_NNP Products_NNPS ,_, Calabasas_NNP ,_,
          CA_NNP )_) ,_, and_CC 100_CD μg_NN /_NN ml_NN gentamycin_NN sulfate_NN (_( Gemini_NNP
          Bio-_NNP Products_NNPS ,_, Calabasas_NNP ,_, CA_NNP )_) ._. Selection_NN pressure_NN was_VBD
          maintained_VBN by_IN the_DT presence_NN of_IN 1_CD mg_NN /_NN ml_NN G_NNP 418_CD sulfate_NN (_( Life_NNP
          Technologies_NNPS ,_, Inc_NNP ._. )_) in_IN the_DT culture_NN media_NNS ,_, which_WDT was_VBD kept_VBN
          at_IN 37_CD °_NN C_NNP in_IN 7_CD %_NN CO_NNP 
          2_CD /_NN humidified_JJ air_NN and_CC was_VBD changed_VBN
          every_DT 3_CD -_: 4_CD days_NNS ._.
        
        
          Cell_NNP treatment_NN and_CC the_DT immunoprecipitation_NN (_( IP_NNP )_) of_IN
          the_DT δ-_NN OR_NNP or_CC the_DT EGFR_NNP
          C_NNP 6_CD -_: δOR_NN or_CC HEK-δOR_NNP cells_NNS were_VBD not_RB treated_VBN until_IN they_PRP
          reached_VBD 80_CD -_: 90_CD %_NN confluency_NN ._. Relative_NNP levels_NNS of_IN receptor_NN
          expression_NN were_VBD continuously_RB measured_VBN among_IN cell_NN types_NNS by_IN
          radioligand_NN binding_JJ assays_NNS [_NN 28_CD ]_NN to_TO insure_VB that_IN all_DT
          cells_NNS used_VBN expressed_VBD 1_CD -_: 2_CD pmol_NN /_NN mg_NN protein_NN of_IN
          3_CD H-_NNP diprenorphine_NN (_( 3_CD H-DIPR_NNP ;_: 3_CD H-DIPR_NNP ,_, 54_CD Ci_NNP /_NN mmol_NN ,_,
          Amersham_NNP ;_: 0_CD ._. 1_CD -_: 1_CD ._. 5_LS nM_NN )_) binding_JJ ._. Sixteen_NNP hours_NNS before_IN the_DT
          addition_NN of_IN drugs_NNS ,_, the_DT culture_NN medium_NN was_VBD removed_VBN and_CC
          replaced_VBN by_IN fresh_JJ serum-free_JJ DMEM_NNP ._. All_DT
          inhibitors_NNS /_NN antagonists_NNS were_VBD added_VBN at_IN least_JJS thirty_CD minutes_NNS
          before_IN opioid_NN agonists_NNS or_CC EGF_NNP ._. After_IN a_DT five-minute_JJ opioid_NN
          or_CC EGF_NNP incubation_NN ,_, the_DT cell_NN monolayers_NNS were_VBD rinsed_JJ twice_RB
          with_IN ice_NN cold_JJ phosphate-buffered_JJ saline_NN (_( PBS_NNP )_) ,_, and_CC the_DT
          cells_NNS were_VBD solubilized_JJ by_IN the_DT addition_NN of_IN 300_CD μl_NN of_IN
          solubilization_NN buffer_NN (_( 50_CD mM_NN Tris-_NNP HCl_NNP /_NN Base_NNP (_( pH_NN 7_CD ._. 4_LS )_) ,_, 1_CD %_NN
          Triton_NNP X-_NNP 100_CD ,_, 10_CD %_NN glycerol_NN ,_, 1_CD ._. 5_CD mM_NN MgCl_NNP 
          2_CD ,_, 1_CD ._. 0_CD mM_NN CaCl_NNP 
          2_CD ,_, 300_CD mMNaCI_NN ,_, 1_CD mM_NN NaVO_NNP 
          3_CD ,_, and_CC the_DT protease_NN inhibitors_NNS
          leupeptin_NN (_( 100_CD μg_NN /_NN ml_NN )_) ,_, PMSF_NNP (_( 100_CD μM_NN )_) ,_, and_CC aprotinin_NN (_( 100_CD
          μg_NN /_NN ml_NN )_) )_) for_IN 60_CD minutes_NNS at_IN +_NN 4_CD °_NN C_NNP ._. Soluble_NNP proteins_NNS were_VBD
          isolated_VBN by_IN centrifugation_NN at_IN 30_CD ,_, 000_CD g_SYM for_IN ten_CD minutes_NNS at_IN
          +_NN 4_CD °_NN C_NNP ._. Primary_JJ cell_NN lysates_NNS were_VBD analyzed_VBN for_IN protein_NN
          concentration_NN using_VBG the_DT Bio-_NNP Rad_NNP method_NN ._. A_DT mouse_NN
          monoclonal_NN antibody_NN raised_VBD against_IN the_DT FLAG-epitope_NNP
          (_( Flag-_NNP M_NNP 
          1_CD antibody_NN (_( 2_CD -_: 5_CD μg_NN /_NN μl_NN )_) ,_, Sigma_NNP
          Chemical_NNP ,_, St_NNP ._. Louis_NNP ,_, Mo_NNP ._. )_) was_VBD used_VBN to_TO immunoprecipitate_NN
          the_DT tagged_VBN δ-_NN OR_NNP from_IN the_DT cell_NN lysates_NNS ,_, and_CC a_DT murine_NN
          anti-_NN EGFR_NNP antibody_NN (_( (_( 5_CD μg_NN /_NN μl_NN )_) clone_NN LA_NNP 22_CD ;_: Upstate_NNP
          Biotechnology_NNP ,_, Lake_NNP Placid_NNP ,_, NY_NNP )_) was_VBD used_VBN to_TO
          immunoprecipitate_NN out_RP the_DT EGFR_NNP ._. Antibodies_NNP to_TO the_DT insulin_NN
          (_( C-_NNP 19_CD epitope-β_JJ subunit_NN ;_: rabbit_NN polyclonal_NN IgG_NNP (_( 5_CD μg_NN /_NN μl_NN )_) )_)
          and_CC PDGF_NNP receptor_NN (_( C-_NNP 20_CD epitope_NN ;_: rabbit_NN polyclonal_NN IgG_NNP (_( 5_CD
          μg_NN /_NN μl_NN )_) )_) were_VBD purchased_VBN from_IN Santa_NNP Cruz_NNP Biotechnology_NNP
          (_( Santa_NNP Cruz_NNP ,_, CA_NNP )_) ._. Immunoprecipitation_NNP of_IN all_DT receptor_NN
          types_NNS was_VBD performed_VBN using_VBG magnetic_JJ Dynabeads_NNP (_( Dynal_NNP
          Bioscience_NNP ,_, Lake_NNP Success_NNP ,_, NY_NNP )_) coated_VBN with_IN anti-mouse_JJ or_CC
          anti-rabbit_JJ IgG_NNP and_CC used_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS
          instructions_NNS ._. Proteins_NNPS were_VBD prepared_VBN for_IN SDS-PAGE_NNP by_IN
          boiling_VBG them_PRP in_IN 2_CD ×_NN Lammeli_NNP 's_POS sample_NN buffer_NN and_CC stored_VBD at_IN
          -_: 70_CD °_NN C_NNP until_IN used_VBN ._.
        
        
          Immunoblotting_NNP for_IN the_DT presence_NN of_IN phosphorylated_JJ
          MAPK_NNP (_( ERK_NNP 1_CD /_NN 2_LS )_) and_CC phosphorylated_JJ tyrosines_NNS
          SDS_NNP PAGE_NNP and_CC immunoblotting_VBG (_( IB_NNP )_) were_VBD performed_VBN
          following_VBG the_DT methods_NNS contained_VBD in_IN a_DT previous_JJ report_NN [_NN 11_CD
          ]_NN ,_, and_CC all_DT procedures_NNS were_VBD performed_VBN at_IN room_NN temperature_NN
          unless_IN otherwise_RB noted_VBD ._. Proteins_NNPS (_( 5_CD -_: 20_CD μg_NN /_NN lane_NN )_) were_VBD
          separated_VBN by_IN using_VBG 10_CD -_: 20_CD %_NN acrylamide_NN gels_NNS ,_, and_CC
          electroblotted_JJ onto_IN nitrocellulose_NN membranes_NNS ._.
          Non-specific_NNP binding_JJ sites_NNS were_VBD blocked_VBN by_IN incubating_VBG the_DT
          nitrocellulose_NN for_IN 60_CD minutes_NNS in_IN blocking_VBG buffer_NN (_( 25_CD mM_NN
          Tris-_NNP HCl_NNP /_NN Base_NNP ,_, 150_CD mM_NN NaCl_NNP ,_, 0_CD ._. 05_CD %_NN Tween-_NNP 20_CD ,_, and_CC 3_CD %_NN nonfat_JJ
          dry_JJ milk_NN )_) ._. For_IN the_DT identification_NN of_IN the_DT activated_VBN form_NN
          of_IN ERK_NNP (_( pERK_NN )_) from_IN primary_JJ cell_NN lysates_NNS ,_, we_PRP used_VBD an_DT
          antibody_NN raised_VBD against_IN pERK-_NN 1_CD /_NN 2_CD (_( 1_CD :_: 5_CD ,_, 000_CD dilution_NN in_IN
          blocking_VBG solution_NN ,_, Santa_NNP Cruz_NNP Biotechnology_NNP ,_, Santa_NNP Cruz_NNP ,_,
          CA_NNP )_) ._. Total_NNP MAPK_NNP levels_NNS were_VBD quantified_VBN using_VBG the_DT ERK-_NNP 1_CD
          antibody_NN (_( C-_NNP 16_CD epitope_NN ;_: 1_CD :_: 5_CD ,_, 000_CD dilution_NN in_IN blocking_VBG
          solution_NN )_) ,_, which_WDT was_VBD also_RB obtained_VBN from_IN Santa_NNP Cruz_NNP
          Biotechnology_NNP (_( Santa_NNP Cruz_NNP ,_, CA_NNP )_) ._. Mouse_NNP monoclonal_NN
          antibodies_NNS raised_VBD against_IN phosphorylated_JJ tyrosines_NNS (_( clone_NN
          PY_NNP 20_CD (_( 1_CD :_: 2_CD ,_, 000_CD dilution_NN )_) ,_, Santa_NNP Cruz_NNP Biotechnology_NNP ,_, Santa_NNP
          Cruz_NNP ,_, CA_NNP )_) were_VBD used_VBN to_TO identify_VB tyrosine_NN phosphorylated_JJ
          EGFR_NNP or_CC δ-_NN ORs_NNP ._. Incubation_NNP with_IN all_DT primary_JJ antibodies_NNS was_VBD
          carried_VBN on_IN overnight_JJ at_IN +_NN 4_CD °_NN C_NNP ._. Membranes_NNP were_VBD then_RB
          incubated_JJ for_IN 60_CD minutes_NNS in_IN the_DT presence_NN of_IN a_DT
          goat-anti-mouse_JJ secondary_JJ antibody_NN linked_VBN to_TO
          horseradish-peroxidase_JJ (_( 1_CD :_: 2_CD ,_, 000_CD )_) at_IN room_NN temperature_NN ._.
          Immunoreactive_NNP proteins_NNS were_VBD visualized_JJ using_VBG a_DT
          horseradish_NN peroxidase-sensitive_JJ ECL_NNP chemiluminescent_NN
          Western_NNP blotting_VBG (_( WB_NNP )_) kit_NN (_( Pierce_NNP )_) ._.
        
        
          Data_NNP Analysis_NNP and_CC statistical_JJ methods_NNS
          Radioligand_NNP binding_JJ curves_NNS (_( to_TO determine_VB k_NN 
          D_NNP and_CC B_NNP 
          max_NN )_) were_VBD generated_VBN ,_, and_CC all_DT
          regression_NN analyses_NNS were_VBD performed_VBN using_VBG the_DT LIGAND_NNP
          curve-fitting_JJ program_NN [_NN 29_CD ]_NN ._. Graphs_NNP were_VBD produced_VBN using_VBG
          Sigmaplot_NNP for_IN Windows_NNP (_( version_NN 4_CD ._. 0_CD )_) ._. Images_NNP of_IN
          immunoreactive_JJ bands_NNS were_VBD captured_VBN on_IN x-ray_JJ film_NN and_CC
          analyzed_VBD using_VBG the_DT MCID_NNP morphometric_JJ system_NN (_( Imaging_NNP
          Research_NNP Inc_NNP ._. ,_, Ontario_NNP ,_, Canada_NNP )_) ._. All_DT immunochemical_JJ
          assays_NNS were_VBD performed_VBN at_IN least_JJS three_CD times_NNS ,_, although_IN
          results_NNS from_IN a_DT single_JJ experiment_NN are_VBP sometimes_RB shown_VBN for_IN
          clarity_NN ._. One-way_NNP and_CC two-way_JJ analyses_NNS of_IN variance_NN (_( ANOVA_NNP )_)
          and_CC the_DT post-hoc_JJ Tukey_NNP test_NN were_VBD used_VBN for_IN multiple_JJ
          comparisons_NNS at_IN a_DT minimum_JJ significance_NN level_NN of_IN p_NN ≤_NN 0_CD ._. 05_CD ._.
          Student_NNP 's_POS t-test_JJ was_VBD substituted_VBN for_IN the_DT ANOVA_NNP for_IN simple_JJ
          two-sample_JJ tests_NNS at_IN the_DT same_JJ significance_NN level_NN ._.
          Statistical_NNP data_NNS are_VBP expressed_VBN as_IN mean_NN ±_NN standard_JJ error_NN
          (_( SE_NNP )_) of_IN the_DT indicated_VBN number_NN of_IN observations_NNS ._.
        
      
    
  
